<DOC>
	<DOCNO>NCT02187497</DOCNO>
	<brief_summary>The pharmacokinetic profile BIBR 277 single dose give capsule form hypertensive evaluate . The result present study use Japanese population pharmacokinetics analysis</brief_summary>
	<brief_title>Pharmacokinetics BIBR 277 Hypertensive Patients</brief_title>
	<detailed_description />
	<mesh_term>Telmisartan</mesh_term>
	<criteria>Age : &gt; =20 year Sex : Either male female Patient status : Either inpatient outpatient , provide patient available hospitalisation day trial medication administration morning day administration BP : Sitting systolic diastolic blood pressure ( SBP DBP ) take day administration &gt; = 150 mmHg &gt; = 90 mmHg , respectively . Patients undergoing treatment antihypertensive exclude provide criterion satisfy . Malignant hypertension Renovascular hypertension Severe heart failure ( NYHA functional class III IV ) , unstable angina pectoris , history myocardial infarction ( within 6 month onset ) Atrioventricular conduction disturbance ( degree II III ) , atrial fibrillation , serious arrhythmia Symptoms cerebrovascular disorder Serious hepatic dysfunction Renal function disorder ( serum creatinine &gt; = 4.0 mg/dL ) Known hypersensitivity angiotensin II receptor antagonist Hyperkalaemia ( potassium &gt; = 5.5 milliequivalent per liter ( mEq/L ) ) Treatment investigational drug within 6 month initiation present study Pregnant , breast feeding , possibly pregnant plan become pregnant study Previous treatment trial medication present study Otherwise judge ineligible investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>